{"schema_version":"secwatch.filing_event.v1","accession":"0001006837-25-000044","form_type":"8-K","ticker":"VATE","cik":"0001006837","company_name":"INNOVATE Corp.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.138324+00:00","generated_at":"2026-05-22T10:26:58.554390+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"INNOVATE Q1 revenue $274.2M (-13% YoY); net loss widens to $24.8M; MediBeacon TGFR gets FDA approval","bullets":["Revenue $274.2M, down 13% YoY; net loss attributable to common $24.8M ($1.89 per share), vs $17.7M loss YoY.","DBM Global revenue $264.9M (-14% YoY); adjusted backlog $1.4B, added over $500M in new awards.","MediBeacon TGFR system received FDA approval in Jan to assess kidney function; also NMPA China approval.","Life Sciences R2 revenue tripled to $3.1M; unit sales up 163% YoY.","Spectrum revenue $6.2M; signed contract for two new OTA networks; datacasting revenue expected by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001006837-25-000044","json":"https://secwatch.observer/filing/0001006837-25-000044.json","markdown":"https://secwatch.observer/filing/0001006837-25-000044.md","text":"https://secwatch.observer/filing/0001006837-25-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006837/000100683725000044/0001006837-25-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006837/000100683725000044/hchc-20250506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T10:26:58.554390+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}